Revolutionizing Pediatric Cancer Research with PDXs
In this episode of the HemaSphere podcast, host Dr Charles de Bock discusses the critical role of mouse models in understanding leukemogenesis and hematopoiesis with Prof Richard Lock. They explore the significance of patient-derived xenografts (PDXs) in preclinical testing, the challenges faced in generating PDXs for acute myeloid leukemia (AML), and the importance of molecular characterization. The conversation also covers the objective response criteria in drug testing, the innovative single mouse trial approach, and the future of immunotherapy testing in PDX models.
Revolutionizing Pediatric Cancer Research with PDXs is on our website and all major podcast platforms (Spotify, Apple Podcast, and more). Listen and enjoy casual, insightful discussions about #hematology research.
You can find the referenced article, The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphobloastic leukemia, in full and open access here on the HemaSphere website
URLs mentioned in the recording:
